Skip to main content
Triangle logo TriangleGet started

Azacitidine (NCT07304011)

Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent: a one-minute explainerNCT073040111 min

Azacitidine trial for Acute Myeloid Leukemia (NCT07304011). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with IDH1-R132-mutated acute myeloid leukemia in remission after no more than four cycles of first-line venetoclax plus a hypomethylating drug. Previous IDH1-inhibitor treatment is excluded.

The idea: stop venetoclax and give oral olutasidenib plus injected azacitidine for up to four cycles, then olutasidenib alone. Olutasidenib blocks mutant IDH1, aiming to restore cell maturation; azacitidine changes DNA methylation. Researchers track relapse, treatment failure and safety.

This phase 2 study plans 28 patients. Brian Jonas leads at UC Davis; two US locations list recruitment.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.